Last updated: September 7, 2026
TWINRIX is GSK’s combined hepatitis A and hepatitis B vaccine for adults and children. Its commercial position is based on dosing convenience, travel-medicine demand, and institutional procurement rather than exclusivity from a current patent barrier. GSK does not disclose TWINRIX revenue separately, so its financial trajectory must be assessed through GSK’s broader vaccines segment, epidemiology, vaccination policy, pricing, and competitive substitution.
TWINRIX remains commercially relevant because it reduces the number of injections required to immunize against two infections. Its main constraints are the maturation of the hepatitis A and B vaccine markets, competition from separate vaccines, public-sector tender pricing, and the limited number of indications that require simultaneous protection.
What is TWINRIX and who manufactures it?
TWINRIX is a fixed-dose combination vaccine containing inactivated hepatitis A virus and recombinant hepatitis B surface antigen. GSK manufactures and markets the product through its vaccines business. The U.S. product is approved for adults and pediatric patients aged 1 year and older, with separate adult and pediatric presentations.[1]
| Attribute |
TWINRIX profile |
| Manufacturer |
GSK plc |
| Product type |
Combination prophylactic vaccine |
| Components |
Inactivated hepatitis A vaccine and recombinant hepatitis B vaccine |
| U.S. indication |
Active immunization against hepatitis A and hepatitis B |
| Standard adult schedule |
0, 1, and 6 months |
| Accelerated adult schedule |
0, 7, and 21-30 days, followed by a 12-month dose |
| Administration |
Intramuscular injection |
| U.S. regulatory category |
FDA-licensed biologic vaccine |
| Primary use cases |
Travel, occupational exposure, risk-based vaccination, and combined protection |
| Main alternatives |
Havrix, Engerix-B, Heplisav-B, Vaqta, and other hepatitis A or B vaccines |
The product’s value proposition is operational. Patients receive protection against two diseases through one branded regimen, while providers can simplify scheduling and inventory management.
How large is the market for TWINRIX?
The addressable market is the combined market for hepatitis A and hepatitis B vaccination, but TWINRIX captures only the subset of patients for whom simultaneous protection is clinically or operationally useful.
Demand comes from four principal channels:
- International travelers visiting areas with hepatitis A or B transmission.
- Adults with occupational, behavioral, medical, or household exposure risks.
- Adolescents and adults who remain unvaccinated against hepatitis B.
- Employers, military organizations, universities, correctional systems, and public-health programs.
The travel segment supports private-market pricing, while government and institutional purchasing creates volume but applies greater price pressure. Hepatitis B vaccination has a broader long-term opportunity because the CDC recommends universal adult hepatitis B vaccination for adults aged 19 through 59 and for adults aged 60 and older with risk factors or on request.[2]
TWINRIX does not automatically capture the full hepatitis B opportunity. Many patients need hepatitis B vaccination without hepatitis A vaccination and may receive a monovalent product instead. Conversely, travelers may receive hepatitis A vaccination alone when hepatitis B risk is limited.
Which patients are most likely to receive TWINRIX?
TWINRIX is most commercially attractive when a patient requires both vaccines and values a shorter or more coordinated vaccination process. Typical examples include:
- Travelers requiring hepatitis A and hepatitis B protection.
- Healthcare workers and emergency responders with dual exposure risks.
- Patients with chronic liver disease who need protection against additional viral hepatitis.
- Individuals with behavioral or occupational exposure to blood or body fluids.
- Patients who need accelerated vaccination before travel or deployment.
The product is less competitive when a payer or public-health program purchases hepatitis A and hepatitis B separately at lower unit cost.
What is GSK’s financial trajectory for TWINRIX?
GSK does not report TWINRIX sales as a separate revenue line. The product is included within the company’s vaccines portfolio, and public filings do not provide a standalone TWINRIX sales history, operating margin, volume figure, or geographic revenue split.[3]
GSK’s vaccines segment generated roughly £9 billion in annual sales in the 2023-2024 period, driven primarily by larger products such as Shingrix, Arexvy, and established vaccines. TWINRIX is a small contributor relative to those products. Its sales trajectory therefore cannot be inferred from total vaccines growth on a one-for-one basis.[3,4]
| Financial question |
Publicly disclosed answer |
| TWINRIX annual revenue |
Not separately disclosed by GSK |
| TWINRIX gross margin |
Not separately disclosed |
| TWINRIX unit volume |
Not separately disclosed |
| TWINRIX regional sales |
Not separately disclosed |
| GSK vaccines segment sales |
Reported in aggregate |
| Main GSK vaccines growth drivers |
Shingrix, Arexvy, RSV, meningococcal, and other portfolio products |
| Financial outlook for TWINRIX |
Mature, recurring vaccine revenue with no separately reported growth target |
The financial profile is therefore best characterized as mature and durable rather than high growth. Revenue is likely influenced by travel recovery, vaccination policy, seasonal demand, public procurement cycles, and pricing discipline. It is not a principal driver of GSK’s consolidated valuation or vaccines-segment growth.
What market factors are driving TWINRIX sales?
Travel recovery
International travel supports demand for hepatitis A vaccination and creates a natural use case for combined hepatitis A and B protection. Travel clinics, pharmacies, occupational-health providers, and primary-care practices are important channels.
Travel demand is seasonal and sensitive to economic conditions. A weaker travel environment can reduce private-pay vaccination, while renewed travel activity can produce short-term volume increases.
Universal adult hepatitis B vaccination
The CDC’s expanded adult hepatitis B recommendation increases the overall market for hepatitis B vaccination.[2] The policy does not require TWINRIX. Monovalent hepatitis B products often remain the default when hepatitis A protection is not indicated.
This creates a mixed commercial effect. The policy expands the number of adults eligible for hepatitis B vaccination but does not ensure that the combination product captures those vaccinations.
Provider convenience
TWINRIX can reduce the complexity of administering two vaccines. The accelerated schedule is particularly relevant for travelers or workers facing imminent exposure. However, accelerated vaccination requires a follow-up dose at 12 months, creating a compliance risk.
Public procurement and tender pricing
Government contracts typically prioritize price, supply reliability, and schedule flexibility. Combination products can have procurement advantages when they replace two separate injections, but they can also face price competition from lower-cost monovalent vaccines.
Supply and manufacturing
Vaccines require specialized antigen production, formulation, filling, quality testing, cold-chain logistics, and regulatory release. These capabilities create operational barriers for new entrants. The barriers are manufacturing and regulatory in nature, not necessarily patent-based.
How does TWINRIX compare with competing vaccines?
TWINRIX’s principal competition comes from products that vaccinate against hepatitis A or hepatitis B separately. There are fewer direct combination competitors than substitute products.
| Product |
Manufacturer |
Protection |
Competitive relationship |
| TWINRIX |
GSK |
Hepatitis A and B |
Direct combination competitor |
| Havrix |
GSK |
Hepatitis A |
Internal substitute when hepatitis B is unnecessary |
| Engerix-B |
GSK |
Hepatitis B |
Internal substitute when hepatitis A is unnecessary |
| Vaqta |
Merck |
Hepatitis A |
Monovalent alternative |
| Heplisav-B |
Dynavax |
Hepatitis B |
Adult hepatitis B alternative with a two-dose schedule |
| Recombivax HB |
Merck |
Hepatitis B |
Monovalent hepatitis B alternative |
| Separate hepatitis A plus hepatitis B products |
Multiple suppliers |
Both diseases |
Substitute regimen using two products |
Heplisav-B has a differentiated adult hepatitis B schedule that can be attractive when rapid completion is more important than combined hepatitis A coverage.[5] TWINRIX’s advantage is breadth of protection in one regimen; its disadvantage is that patients receive an unnecessary antigen if they need only one vaccine.
What is the FDA regulatory status of TWINRIX?
TWINRIX is FDA-approved and marketed as a preventive vaccine. Its regulatory position is established, with licensed adult and pediatric formulations and approved dosing schedules described in the prescribing information.[1]
The product is not a small-molecule drug that faces ordinary ANDA substitution. A competing vaccine would generally require its own biologics or vaccine approval, supported by manufacturing, immunogenicity, safety, and quality data.
TWINRIX also does not face a conventional biosimilar threat. Biosimilar competition is relevant mainly to therapeutic biologics with comparable reference-product pathways. Vaccines are regulated through product-specific biologics frameworks, and a competing hepatitis A/B vaccine would not normally enter the market as a simple interchangeable biosimilar to TWINRIX.
What is the Orange Book status of TWINRIX?
TWINRIX is not best analyzed through the conventional Orange Book patent-listing framework used for small-molecule drugs. The product is an FDA-licensed vaccine biologic, and competitive entry depends primarily on independent regulatory approval, manufacturing capability, supply, and commercial access.
No active, commercially decisive Orange Book patent barrier is publicly identified as the principal constraint on U.S. competition for TWINRIX. The absence of an Orange Book-based entry barrier does not mean that a competitor can immediately launch. A new supplier would still need a validated manufacturing process, clinical and immunogenicity support, FDA approval, and sufficient production capacity.
What patents protect TWINRIX?
The original commercial protection for TWINRIX was associated with product development, vaccine composition, immunogenicity, manufacturing, and formulation technology. Any early U.S. patents connected to the product’s original development would be more than 20 years old or approaching the end of their ordinary patent terms, depending on the specific patent and adjustment history.
GSK does not identify TWINRIX as a current patent-protected growth product in its principal annual-report disclosures.[3,4] Public information does not establish a current patent estate that would materially delay an independently approved competing hepatitis A/B vaccine.
The most important continuing barriers are:
- Proprietary production know-how.
- Antigen quality and consistency.
- Manufacturing validation.
- Regulatory comparability and clinical evidence.
- Cold-chain distribution.
- Institutional purchasing access.
- Provider and travel-clinic adoption.
These barriers can preserve commercial share after patent expiry, but they do not create the same legal exclusivity as an unexpired composition-of-matter patent.
Are there Paragraph IV challenges to TWINRIX?
Paragraph IV litigation is not the central generic-entry mechanism for TWINRIX. Paragraph IV certifications apply to ANDA applicants challenging listed patents for small-molecule products. A competing hepatitis A/B vaccine would generally pursue its own biologics or vaccine approval pathway rather than file a standard ANDA with a Paragraph IV certification.
No major publicly reported Paragraph IV campaign is identified as a current threat to TWINRIX. The more realistic competitive risk is product-level entry by an independently approved combination vaccine or increased use of monovalent hepatitis A and B products.
What litigation and settlement agreements affect TWINRIX?
No major current patent litigation or settlement agreement is publicly identified as a material commercial event affecting TWINRIX’s U.S. market position. GSK’s public litigation disclosures cover broader corporate matters and do not identify TWINRIX as a current high-value patent dispute.[3,4]
The absence of disclosed litigation reduces legal uncertainty but does not eliminate commercial pressure. Vaccine markets can experience share erosion without a court challenge through tender losses, formulary changes, competing schedules, and provider substitution.
What geographic markets are most important for TWINRIX?
TWINRIX has its strongest strategic fit in markets with:
- High outbound travel.
- Broad adult hepatitis B vaccination policies.
- Established private vaccination channels.
- Strong reimbursement for adult immunization.
- Institutional demand from healthcare and occupational groups.
The United States is commercially important because of its private travel-vaccine market and broad hepatitis B recommendations. Europe, Canada, Australia, and selected Asia-Pacific markets offer additional demand, but product names, schedules, reimbursement, and approved age groups vary by jurisdiction.
Local public-health policy can shift the product mix. Countries that purchase monovalent vaccines through centralized tenders may limit TWINRIX volume even when hepatitis A and B vaccination rates are high.
What generic launch risks exist for TWINRIX?
The probability of a conventional generic launch is low because TWINRIX is a vaccine biologic rather than a standard oral chemical drug. The main competitive scenarios are:
| Scenario |
Commercial effect |
Probability profile |
| Monovalent hepatitis A substitution |
Reduces TWINRIX use where hepatitis B is unnecessary |
Ongoing |
| Monovalent hepatitis B substitution |
Reduces TWINRIX use under universal hepatitis B programs |
Ongoing |
| New combination vaccine |
Directly pressures price and share |
Regulatory and manufacturing dependent |
| Public tender loss |
Can reduce regional volume quickly |
Contract dependent |
| Travel-market expansion |
Supports volume and private pricing |
Demand dependent |
| Supply interruption |
Can temporarily shift share to competitors |
Operationally dependent |
TWINRIX’s main downside risk is gradual substitution, not an abrupt patent cliff.
How strong is the TWINRIX patent estate?
The patent estate appears commercially weak as a source of current exclusivity but operationally reinforced by manufacturing complexity and regulatory requirements.
| Protection category |
Current strategic importance |
| Core product patents |
Limited if original terms have expired |
| Formulation patents |
Potentially relevant only if unexpired and jurisdiction-specific |
| Method-of-use patents |
Limited role in routine preventive vaccination |
| Manufacturing know-how |
High operational importance |
| Regulatory approval |
High barrier to independent entry |
| Brand recognition |
Moderate commercial value |
| Distribution and procurement contracts |
Important in institutional markets |
A challenger would face a difficult development program, but not necessarily a strong patent wall.
What is the outlook for TWINRIX revenue?
TWINRIX revenue is likely to remain recurring but mature. Growth depends on increased adult hepatitis B uptake, travel vaccination, broader use among patients with chronic liver disease, and the product’s ability to retain share against monovalent vaccines.
The product is unlikely to be a major driver of GSK’s consolidated growth. GSK’s capital and commercial focus is concentrated on larger vaccines and specialty medicines, while TWINRIX provides established portfolio revenue with lower strategic visibility.[3,4]
The most probable financial trajectory is:
- Stable baseline demand from travel and occupational vaccination.
- Periodic volume increases tied to travel recovery and public-health campaigns.
- Price pressure in institutional and government channels.
- Gradual substitution where patients need only hepatitis A or hepatitis B protection.
- Limited risk of an abrupt patent-driven revenue collapse.
Key Takeaways
- TWINRIX is GSK’s combined hepatitis A and hepatitis B vaccine for adults and children.
- GSK does not disclose TWINRIX revenue separately.
- The product is a mature contributor to GSK’s broader vaccines portfolio, not a principal growth driver.
- Its commercial advantage is combined protection and scheduling convenience.
- Its main competitors are monovalent hepatitis A and hepatitis B vaccines, including Havrix, Engerix-B, Vaqta, Heplisav-B, and Recombivax HB.
- Universal adult hepatitis B vaccination expands the overall market but does not guarantee demand for TWINRIX.
- Conventional generic and Paragraph IV threats are limited because TWINRIX is a biologic vaccine.
- No current patent litigation or settlement is publicly identified as a material threat.
- Manufacturing, regulatory approval, quality control, and procurement access are more important barriers than current patent exclusivity.
- The likely outlook is stable recurring revenue with gradual competitive and pricing pressure.
FAQs About TWINRIX Market and Financial Outlook
Is TWINRIX a biologic or a traditional drug?
TWINRIX is a biologic vaccine licensed by the FDA. It contains inactivated hepatitis A virus and recombinant hepatitis B surface antigen.
Does GSK report TWINRIX sales separately?
No. GSK reports vaccines revenue at the portfolio or segment level and does not provide a standalone TWINRIX revenue line.
Can a generic manufacturer substitute TWINRIX automatically?
No. A competing manufacturer would generally need its own vaccine or biologics approval. Automatic ANDA substitution is not the standard route for a competing hepatitis A/B vaccine.
Is TWINRIX protected by an active U.S. patent?
No current patent barrier is publicly identified as the principal constraint on U.S. competition. Any relevant patent analysis must be performed patent by patent and jurisdiction by jurisdiction.
What is the largest commercial threat to TWINRIX?
The largest threat is substitution by separate hepatitis A or hepatitis B vaccines, particularly when a patient needs protection against only one disease or when public tenders prioritize the lowest acquisition cost.
References
- U.S. Food and Drug Administration. (2023). Twinrix prescribing information. https://www.fda.gov
- Centers for Disease Control and Prevention. (2024). Adult immunization schedule by age and risk condition. https://www.cdc.gov/vaccines
- GSK plc. (2024). Annual report 2023. https://www.gsk.com
- GSK plc. (2025). Annual report 2024. https://www.gsk.com
- U.S. Food and Drug Administration. (2017). Heplisav-B prescribing information. https://www.fda.gov
